Piper Sandler Downgrades POINT Biopharma Global to Neutral, Announces $12.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Edward Tenthoff has downgraded POINT Biopharma Global (NASDAQ:PNT) from Overweight to Neutral and set a price target of $12.5.
October 24, 2023 | 10:35 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
POINT Biopharma Global has been downgraded by Piper Sandler from Overweight to Neutral with a price target of $12.5.
The downgrade from Piper Sandler could potentially lead to a decrease in the stock price of POINT Biopharma Global in the short term. The new price target set by the analyst may also influence investor sentiment and trading behavior.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100